Alzheimer's Disease - Pipeline Review, H2 2013 report provides an overview of the indication’s therapeutic pipeline. This report also reviews key players involved in the therapeutic development for Alzheimer's Disease. Alzheimer's Disease - Pipeline Review, Half Year is built using data and information sourced from publisher proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by publisher team.
Scope
- A snapshot of the global therapeutic scenario for Alzheimer's Disease.
- A review of the Alzheimer's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Alzheimer's Disease pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Alzheimer's Disease.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Alzheimer's Disease pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Spanning over 297 pages, 260 tables and 10 figures, “ Alzheimer's Disease - Pipeline Review, H2 2013 ” report provides information on the therapeutic development for Alzheimer's Disease, complete with latest updates, and special features on late-stage and discontinued projects.
In addition to covering the Alzheimer's Disease Overview, Late Stage Products, Mid Clinical Stage Products, Early Clinical Stage Products, Discovery and Pre-Clinical Stage Products, Companies Involved in Alzheimer's Disease Therapeutics Development, Alzheimer's Disease Therapeutics - Drug Profile Updates, Alzheimer's Disease Therapeutics - Discontinued Products, Alzheimer's Disease Therapeutics - Dormant Products. The report covers 170 companies; few are Bristol-Myers Squibb Company, Johnson & Johnson, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Biogen Idec Inc., OXIS International, Inc., Shionogi & Co., Ltd., NsGene A/S, Amgen Inc., Sanofi-Aventis, AstraZeneca PLC, Eli Lilly and Company. Find all: Pharma and Healthcare Market Research Reports
No comments:
Post a Comment
Note: only a member of this blog may post a comment.